undamentalytics Newsletter

Rajavelu Esther: insider trades

Chief financial officer, Officer at Spero Therapeutics, Inc. No open-market purchases and 6 sales not made under a pre-set plan, reported from November 12, 2024 to May 6, 2026.

What happened after Rajavelu Esther’s sales?

None of these trades can be measured yet: either the window after the report has not finished or the share price was under $5 when it was reported.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Rajavelu Esther: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Spero Therapeutics, Inc. SPRO See Remarks06November 12, 2024May 6, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 6, 2026May 4, 2026 SPRO Sale $63,352 not yetnot yetnot yet
February 9, 2026February 6, 2026 SPRO Sale $207,484 not yetnot yetnot yet
February 4, 2026February 2, 2026 SPRO Sale $40,572 not yetnot yetnot yet
November 12, 2025November 7, 2025 SPRO Sale $95,440 not yetnot yetnot yet
February 5, 2025February 5, 2025 SPRO Sale $16,137 not yetnot yetnot yet
November 12, 2024November 7, 2024 SPRO Sale $53,008 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Rajavelu Esther traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.